Hard Feelings: Allergan/Valeant Merger Fight Colors Tax Reform Hearing
This article was originally published in RPM Report
A Senate hearing on the impact of the US corporate tax code on foreign acquisitions is part of the growing momentum to reshape tax policy in ways that could help American biopharma companies. However, Allergan’s former CEO is having a hard time letting bygones be bygones.
Register for our free email digests: